Case Report: Neoadjuvant chemoimmunotherapy achieving pathological complete response in two cases of stage III EGFR-mutant NSCLC with high PD-L1 expression

Resectable locally advanced EGFR-mutant non-small cell lung cancer (NSCLC) represents a distinct therapeutic challenge. Owing to an inherently immunosuppressive tumor microenvironment—frequently characterized by absence of or low PD-L1 expression and sparse CD8+ tumor-infiltrating lymphocytes—patien...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Diming Wang, Tangbin Liu, Jian Zhao, Bowen Ding, Yongliang Niu
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2026-06-01
Edice:	Frontiers in Oncology
Témata:	EGFR-mutant lung adenocarcinoma neoadjuvant chemoimmunotherapy neoadjuvant immunotherapy NSCLC
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1844982/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!